Focused On Serving Your Needs
  1. Home
  2.  — 
  3. Products Liability
  4.  — Serious Heart or Kidney problems on Invokana or Canagliflozin?

Serious Heart or Kidney problems on Invokana or Canagliflozin?

On Behalf of | Jul 26, 2015 | Products Liability

Serious Heart or Kidney problems on Invokana or Canagliflozin?

O'Malley Tunstall, from our Raleigh and Eastern NC offices are currently investigating cases involving Canagliflozin, Dapagliflozin, and Empagliflozin and serious side effects. These side effects can include:

Kidney failure or impairment

Kidney stones

Fluid/electrolyte problems

Urinary tract infections



The most serious potential side effects, problems and risks caused through the use Invokana (Invokamet) are myocardial infarction (heart attack), kidney damage and ketoacidosis.

Kidney failure occurs when your kidneys stop functioning without the use of dialysis or a kidney transplant

Myocardial infarction (commonly known as a heart attack) is the irreversible death of cells within the heart caused by restriction of blood.

Ketoacidosis (Diabetic ketoacidosis, Ketosis) is a very serious, potentially fatal condition where the acid level in the blood rises dangerously high

Invokana (Canagliflozin) was the first in a new class of diabetes drugs, which work by altering normal kidney functions so that sugar is excreted through the urine.

It was approved in March 2013 by the FDA.

The class of drugs, known as Sodium-Glucose Costransporter-2 (SGLT2) inhibitors, also includes the new medications Farxiga, Glyxambi, Jardiance, and Xigduo XR. They are approved as a second-line drug to treat type 2 diabetes.

Since Invokana was introduced, it has been linked to hundreds of adverse event reports of kidney failure, kidney damage and diabetic ketoacidosis, as well as urinary tract infections, hypersensitivity and weight loss.

Indications: Canagliflozin are TGA approved as an adjunct to diet and exercise for glycaemic control in adults with type 2 diabetes mellitus

Limitation of use: Not recommended in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis

FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [05-15-2015]

The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines Canagliflozin, Dapagliflozin, and Empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization.

So if you have Serious Heart or Kidney problems on Invokana or Canagliflozin contact O'Malley Tunstall. We will be glad to obtain your medical records and review from either our Raleigh or Eastern NC law offices.


* -->